



EXHIBIT A

CIRRICULUM VITAE

MATTHEW CLAYTON COFFEY

Date of birth: 9 March 1971

Place of birth: Medicine Hat, Alberta

Citizenship: Canadian

Marital Status: Married

Address: Oncolytics Biotech Inc.
210, 1167 Kensington Crescent NW
Calgary, Alberta T2N 1X7

Bus: (403) 670-0711
Res: (403) 244-8373
Fax: (403) 283-0858
Email: mattonc@aol.com

Degrees

1998	Ph.D., University of Calgary, (Oncology)
1993	B.Sc., University of Calgary, (Cellular, Molecular, & Microbial Biology)

Courses

Sept/2002	Classroom Patent Bar Review, Patent Resources Group, Glendale, CA
July/2002	Introduction to Good Clinical Practices & Auditing, Drug Information Association, Montreal, PQ
May/2002	Patent Law for Managers, Engineers & Scientists, Patent Resources Group, Florida
Feb/2002	Clinical Trials for Anti-Cancer Drugs, Institute for International Research, San Francisco, CA
Jun/2001	Mastering Clinical Research Project Management in Canada, Institute for International Research, Toronto, Ontario
Apr/2001	Patent Law for Managers, Engineers, and Scientists, The Center for Professional Advancement, East Brunswick, NJ

Positions

Jul/99-present	Vice President, Product Development, Oncolytics Biotech Inc.
Jul/99-May/00	Chief Financial Officer, Oncolytics Biotech Inc.
Mar/99-Jul/99	Project Manager, Synsorb Biotech Inc.
Apr/98-Apr/99	Co-founded Oncolytics Biotech Inc. Appointed Corporate Secretary

Awards

1994-8	Alberta Heritage Foundation for Medical Research (AHFMR)
--------	--

Publications

1. Hirasawa K, Nishikawa SG, Norman KL, **Coffey MC**, Thompson BG, Yoon CS, Waisman DM, Lee PW. Systemic reovirus therapy of metastatic cancer in immunocompetent mice. *Cancer Res* 2003 Jan 15;63(2): 348-53
2. Morris DG, Forsyth PA, Paterson AH, Fonseca K, DiFrancesco LM, Thompson BG, **Coffey MC**, Tom Baker Cancer Centre, Calgary, Ab; Oncolytics Biotech Inc., Calgary, Ab. A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. *Proceedings of ASCO Volume 21* 2002.
3. Lakshminarayanan S, Wu F, **Coffey M**, Thompson B, Kodihalli S, BioReliance Corporation, Rockville MD; Oncolytics Biotech Inc., Calgary, Ab. Scalable Purification Procedure for Reolysin for Cancer Therapy
4. Norman KL, **Coffey MC**, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW. Reovirus Oncolysis of Human Breast Cancer. *Human Gene Therapy* 2002 March 20
5. Zhao YG, Gilmore R, Leone G, **Coffey MC**, Weber B, Lee PW. Hsp90 phosphorylation is linked to its chaperoning function: Assembly of the reovirus cell attachment protein. *J Biol Chem* 2001 Jul 3
6. **Coffey, MC**, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. *Science* 1998 Nov 13; 282 (5392):1244-6
7. Strong JE, **Coffey MC**, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis; usurpation of the Ras signaling pathway by reovirus. *EMBO J* 1998 Jun 15;17(12):3351-62
8. Gilmore R, **Coffey MC**, Lee PW. Active participation of Hsp90 in the biogenesis of the trimeric reovirus cell attachment protein signal. *J Biol Chem* 1998 Jun 12;273(24):15227-33
9. Gilmore R, **Coffey MC**, Leone G, McLure K, Lee PW. Co-translational trimerization of the reovirus cell attachment protein. *EMBO J* 1996 Jun 3;15(11):2651-8
10. Leone G, **Coffey MC**, Gilmore R, Duncan R, Maybaum L, Lee PW. C-terminal trimerization, but not N-terminal trimerization, of the reovirus cell attachment protein is a posttranslational and Hsp70/ATP-dependent process. *J Biol Chem* 1996 Apr 5;271(14):8466-71
11. Lakshminarayanan S, Huang M, Kodihalli S, **Coffey MC**, Thompson B, Wu F. Production and purification of Reolysin[®] for cancer therapy. Abstract 942

Patents

1. United States Patent No. 6,649,157, Thompson BG, **Coffey MC**, Viruses for the treatment of cellular proliferative disorders.
2. United States Patent No. 6,576,234, Thompson BG, **Coffey MC**, Reovirus for the treatment of neoplasia
3. United States Patent No. 6,565,831, Thompson BG, **Coffey MC**, Method of preventing reovirus recognition for the treatment of cellular
4. United States Patent No. 6,528,305, Thompson BG, **Coffey MC** Method of producing infectious reovirus
5. United States Patent No. 6,455,038, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of cellular proliferative disorders
6. European Patent No. 1,003,524, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of neoplasia
7. United States Patent No. 6,344,195, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of neoplasia
8. New Zealand Patent No. 337493, Oncolytics Biotech Inc.: Reovirus for the treatment of neoplasia
9. United States Patent No. 6,261,555, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of neoplasia
10. United States Patent No. 6,110,461, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of neoplasia
11. United States Patent No. 6,136,307, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of cellular proliferative disorders
12. United States Patent No. 6,808,916, **Coffey MC**, Thompson BG, Method of Extracting Virus From Cell Culture
13. United States Patent No. 6,811,775, Lee PW, Strong J, **Coffey MC** Reovirus for the Treatment of Cellular Proliferative Disorders